Crispr cans a next-gen project
The CD70-targeting CTX131 heads for the scrapheap.
Grit enters the in vivo Car-T race
And Vironexis’s second gene therapy-encoded T-cell engager will soon go clinical.
Crispr’s Car-T crunch time
The group could soon provide clarity on CTX112’s regulatory path.
Kyowa joins GSK in Tim-3
Meanwhile, Tango tries again in PRMT5.
Roche doubles down on Poseida
A $1bn buyout gives Roche more allogeneic Car-T projects, plus non-viral gene therapy contenders.
Crispr abandons first-generation Car-T projects
The company hopes that new edits could solve the relapse problem with allogeneic Car-Ts.
